200 SIDNEY STREET, CAMBRIDGE, MA
Stockholders Approve Amendment to 2025 Incentive Award Plan
Investor Presentation
Announces Two Transactions to Strengthen Balance Sheet, Reduce Operating Costs and Extend Projected Operating Cash Runway Well into the First Quarter of 2027
Reports First Quarter 2026 Financial Results and Provides Business Updates
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Executive Appointments - Richard Kender Named Interim CEO at Seres Therapeutics
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Other Events
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
PREM14A